Revenue of the Oncology Molecular Diagnostics Market Predicted to Achieve $10.13 Billion by 2030, Driven by 12.4% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Oncology Molecular Diagnostics Market?
The oncology molecular diagnostics market has witnessed rapid expansion in recent years. Projections indicate a future increase from $5.65 billion in 2025 to $6.34 billion in 2026, at a compound annual growth rate (CAGR) of 12.2%. This historical growth can be ascribed to several factors, including the rising prevalence of cancer, the adoption of PCR and sequencing technologies, increased oncology research funding, the expansion of hospital diagnostic services, and regulatory approvals for molecular tests.
The oncology molecular diagnostics market is projected to experience substantial expansion in the coming years, reaching $10.13 billion by 2030, propelled by a compound annual growth rate (CAGR) of 12.4%. This anticipated growth during the forecast period is primarily fueled by factors such as the increasing adoption of precision oncology, progress in liquid biopsy techniques, the rising need for personalized treatments, AI-powered data interpretation, and the expansion into emerging markets. Key trends anticipated for this period encompass the development of companion diagnostics, the increasing application of liquid biopsy, the broader implementation of biomarker-based testing, a rise in cancer screening initiatives, and a strong demand for prompt and precise cancer detection.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp
What Drivers Are Supporting Technological Adoption In The Oncology Molecular Diagnostics Market?
The increasing demand for personalized medicine is projected to stimulate the growth of the oncology molecular diagnostics market moving forward. Personalized medicine signifies an innovative method in medical treatment and healthcare, customizing medical decisions, practices, interventions, and drug therapies for each individual patient. Oncology molecular diagnostics play a vital role within personalized medicine for cancer patients by enabling customized treatment regimens, optimized drug selection, and more precise, effective, and individualized treatment strategies, ultimately leading to improved patient outcomes and quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, documented that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six in 2022. Therefore, the escalating demand for personalized medicine is actively driving the expansion of the oncology molecular diagnostics market.
Which Segments Are Contributing To The Growth Of The Oncology Molecular Diagnostics Market?
The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing
How Are New Market Trends Shaping The Landscape Of The Oncology Molecular Diagnostics Market?
Leading firms within the oncology molecular diagnostics sector are prioritizing the advancement of genomics technologies, including next-generation cancer genome sequencing, computational analytics, and novel tumor modeling, with the aim of enhancing early cancer detection, identifying mutations, and developing personalized treatment approaches. Such developments boost diagnostic accuracy, cut down on processing times, and cater to the increasing need for precise, localized molecular testing. An example of this is OncoHelix-CoLab, a Canada-based precision oncology provider specializing in genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, which inaugurated a cutting-edge laboratory at Burjeel Medical City in the UAE in May 2024. This facility, established through a partnership between Burjeel Holdings and OncoHelix, reinforces regional diagnostic capacities by allowing intricate molecular and immunology tests to be performed within the region, eliminating the need to send samples internationally. Its specialized services encompass sophisticated assays for various cancers, including prostate cancer, backed by collaborations such as its partnership with Nanostics for the ClarityDX Prostate test.
Who Are The Core Companies Influencing Trends In The Oncology Molecular Diagnostics Market?
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Oncology Molecular Diagnostics Market?
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Oncology Molecular Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3457&type=smp
Browse Through More Reports Similar to the Global Oncology Molecular Diagnostics Market 2026, By The Business Research Company
Diagnostic Imaging Equipment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-imaging-equipment-global-market-report
Diagnostic And Monitoring Ophthalmic Devices And Equipment Global Market Report 2026
Microbiology Diagnostic Devices And Equipment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
